BANZEL is indicated for adjunctive treatment of seizures associated with
Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older,
and in adults.
By clicking checkbox below, you agree that you have read, understand, and agree to these conditions.
In the event that I would like to opt out of receiving further communications, I can request that I be removed from the Eisai contact list at any time by clicking on the "Unsubscribe" link found at the bottom of all email communications from Eisai.
Learn about the efficacy of BANZEL® (rufinamide) in the pivotal trial